Roxadustat + Placebo

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

CKD Anemia

Conditions

CKD Anemia

Trial Timeline

Nov 5, 2012 → Sep 24, 2018

NCT ID

NCT01750190

About Roxadustat + Placebo

Roxadustat + Placebo is a phase 3 stage product being developed by Astellas Pharma for CKD Anemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01750190. Target conditions include CKD Anemia.

What happened to similar drugs?

20 of 20 similar drugs in CKD Anemia were approved

Approved (20) Terminated (5) Active (0)

✅Aranesp®AmgenApproved

✅Epoetin alfa 450 IU/kg once a week + Epoetin alfa 150 IU/kg 3 times a week + Epoetin alfa 450 IU/kg once a week (QW) + Epoetin alfa 150 IU/kg 3 times a week (TIW)Johnson & JohnsonApproved

✅Epoetin AlfaJohnson & JohnsonApproved

✅Roxadustat + rHuEPOAstraZenecaApproved

✅ICL670 + Chelation + No chelationNovartisApproved

✅cera, darbepoetin, epoetin-beta + ESARocheApproved

✅methoxy polyethylene glycol-epoetin beta [Mircera]RocheApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03263091	Phase 3	Terminated	Jan 29, 2018	Jun 20, 2023	Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)
NCT01887600	Phase 3	Completed	Sep 3, 2013	Nov 1, 2017	Anemia in Chronic Kidney Disease in Non-dialysis Patients
NCT01750190	Phase 3	Completed	Nov 5, 2012	Sep 24, 2018	CKD Anemia
NCT00761657	Phase 2	Completed	Nov 1, 2006	Jun 21, 2010	Chronic Kidney Disease

Competing Products

20 competing products in CKD Anemia

See all competitors

Product	Company	Stage	Hype Score
Aranesp®	Amgen	Approved	43
KER-047	Keros Therapeutics	Phase 2	17
LY2787106	Eli Lilly	Phase 1	29
R744 + R744	Chugai Pharmaceutical	Phase 3	40
epoetin beta + placebo	Chugai Pharmaceutical	Phase 3	40
recombinant human erythropoietin + recombinant human erythropoietin placebo	Chugai Pharmaceutical	Phase 3	40
recombinant human erythropoietin + recombinant human erythropoietin	Chugai Pharmaceutical	Phase 3	40
darbepoetin alfa	Amgen	Phase 3	40
Prasugrel	Daiichi Sankyo	Phase 1	29
Prasugrel + Placebo	Daiichi Sankyo	Phase 2	35
roxadustat	Astellas Pharma	Phase 3	40
roxadustat	Astellas Pharma	Phase 3	40
Roxadustat + Darbepoetin alfa	Astellas Pharma	Phase 3	40
Alefacept	Astellas Pharma	Phase 1	21
Roxadustat	Astellas Pharma	Phase 2	35
roxadustat	Astellas Pharma	Phase 1	29
Roxadustat	Astellas Pharma	Pre-clinical	26
Roxadustat + Epoetin Alfa	Astellas Pharma	Phase 3	40
roxadustat + Darbepoetin alfa	Astellas Pharma	Phase 3	40
roxadustat	Astellas Pharma	Phase 3	40